ABL Bio Licenses Brain Delivery Platform to GSK in GBP 2-Billion Neurodegenerative Drug Deal; Shares Jump 17%

MT Newswires Live04-08

South Korean clinical-stage biotech company ABL Bio (KOSDAQ:298380) signed a global licensing deal with British pharmaceutical and biotechnology firm GlaxoSmithKline to develop neurodegenerative disease treatments using its Grabody-B blood-brain barrier shuttle platform.

The agreement includes an upfront and near-term payment of up to 77.1 million pounds, with total milestone payments potentially reaching 2.075 billion pounds, ABL Bio said Sunday.

GlaxoSmithKline will lead the development, manufacturing, and commercialization efforts, while ABL Bio will receive tiered royalties on future sales, the release said.

ABL Bio hit the daily trading limit on Monday, soaring 29.96% to 44,250 won following the deal on Sunday, according to Pulse News.

Shares of the company jumped over 17% in recent trade on Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2525884914?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-04-08 11:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2525884914","market":"nz","top_or_hot":-1,"title":"ABL Bio Licenses Brain Delivery Platform to GSK in GBP 2-Billion Neurodegenerative Drug Deal; Shares Jump 17%","media":"MT Newswires Live","content":"<html><body><p> South Korean clinical-stage biotech company ABL Bio (KOSDAQ:298380) signed a global licensing deal with British pharmaceutical and biotechnology firm GlaxoSmithKline to develop neurodegenerative disease treatments using its Grabody-B blood-brain barrier shuttle platform.</p><p>The agreement includes an upfront and near-term payment of up to 77.1 million pounds, with total milestone payments potentially reaching 2.075 billion pounds, ABL Bio said Sunday.</p><p>GlaxoSmithKline will lead the development, manufacturing, and commercialization efforts, while ABL Bio will receive tiered royalties on future sales, the release said.</p><p>ABL Bio hit the daily trading limit on Monday, soaring 29.96% to 44,250 won following the deal on Sunday, according to Pulse News.</p><p>Shares of the company jumped over 17% in recent trade on Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ABL Bio Licenses Brain Delivery Platform to GSK in GBP 2-Billion Neurodegenerative Drug Deal; Shares Jump 17%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nABL Bio Licenses Brain Delivery Platform to GSK in GBP 2-Billion Neurodegenerative Drug Deal; Shares Jump 17%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-08 11:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> South Korean clinical-stage biotech company ABL Bio (KOSDAQ:298380) signed a global licensing deal with British pharmaceutical and biotechnology firm GlaxoSmithKline to develop neurodegenerative disease treatments using its Grabody-B blood-brain barrier shuttle platform.</p><p>The agreement includes an upfront and near-term payment of up to 77.1 million pounds, with total milestone payments potentially reaching 2.075 billion pounds, ABL Bio said Sunday.</p><p>GlaxoSmithKline will lead the development, manufacturing, and commercialization efforts, while ABL Bio will receive tiered royalties on future sales, the release said.</p><p>ABL Bio hit the daily trading limit on Monday, soaring 29.96% to 44,250 won following the deal on Sunday, according to Pulse News.</p><p>Shares of the company jumped over 17% in recent trade on Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK.UK","symbol_name":"葛兰素史克","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2525884914","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2525884914","pubTimestamp":1744081765,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"South Korean clinical-stage biotech company ABL Bio (KOSDAQ:298380) signed a global licensing deal with British pharmaceutical and biotechnology firm GlaxoSmithKline to develop neurodegenerative disea","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSK.UK":"葛兰素史克","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4532":"文艺复兴科技持仓","BK4007":"制药","GSK":"葛兰素史克","BK4173":"保险经纪商","BK4585":"ETF&股票定投概念","BK4588":"碎股","ABL":"Abacus Global Management"},"translate_title":"ABL Bio以20亿英镑的神经退行性药物交易将Brain Delivery Platform授权给GSK；股价上涨17%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABL":1,"GSK":1,"GSK.UK":0.6},"content_text":"South Korean clinical-stage biotech company ABL Bio (KOSDAQ:298380) signed a global licensing deal with British pharmaceutical and biotechnology firm GlaxoSmithKline to develop neurodegenerative disease treatments using its Grabody-B blood-brain barrier shuttle platform.The agreement includes an upfront and near-term payment of up to 77.1 million pounds, with total milestone payments potentially reaching 2.075 billion pounds, ABL Bio said Sunday.GlaxoSmithKline will lead the development, manufacturing, and commercialization efforts, while ABL Bio will receive tiered royalties on future sales, the release said.ABL Bio hit the daily trading limit on Monday, soaring 29.96% to 44,250 won following the deal on Sunday, according to Pulse News.Shares of the company jumped over 17% in recent trade on Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.1","shortVersion":"4.33.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2525884914"}